Lallemand Health Solutions

Lacidofil

A unique combination, 26 clinical studies

An increasing level of evidence in GUT-RELATED fields and paving the way for new applications beyond the gut

A specific probiotic formula combining:

L. rhamnosus Rosell^®-11
L. helveticus Rosell^®-52

Commercially available since 1995 with a pharmacovigilance program showing safe use.

Now marketed under various registrations status in more than 20 countries incl. USA, Canada, France, UK, Poland, S. Korea…

An extensive documentation on single strains and consistent in vivo results on the combination.

Supported by 26 CLINICAL STUDIES, 13 in children / 13 in adults (incl. 2 in pregnant women): 1,700+ participants enrolled.

© 2024 Lallemand Inc. All right reserved.
The information contained herein is business-to-business information and is not intended for the final consumer. It is based on our research and development work and is, to the best of our knowledge, reliable. Lallemand Health Solutions does not assume any liability resulting from the use of its products, as conditions of use are beyond our control. The business-to-business information provided should not be used as a substitute for any form of advice. In all instances, producers and marketers should check local regulatory requirements before use as different claims may be made depending on the regulations applicable in each country.